Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.46 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
| ▸ | AAK1 | Q2M2I8 | 8/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.38 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.36 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.36 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29430592 | 1.00 | TRPA1 (0.46) | TRPA1EGLN2GPR119AAK1CYP17A1 | |
| SCHEMBL24121371 | 0.85 | TRPA1 (0.37) | TRPA1EGLN2AAK1ARRXFP1 | |
| SCHEMBL197226 | 0.84 | AAK1 (0.43) | AAK1CYP17A1KCNQ4KCNQ5RXFP1 | |
| SCHEMBL29430661 | 0.84 | HSP90AA1 (0.37) | TRPA1EGLN2AAK1RORC | |
| SCHEMBL20096644 | 0.84 | TRPA1 (0.46) | TRPA1EGLN2GPR119AAK1CYP17A1 | |
| SCHEMBL6162611 | 0.82 | TRPA1 (0.38) | TRPA1EGLN2AAK1KCNQ4KCNQ5 | |
| SCHEMBL22073609 | 0.82 | TRPA1 (0.40) | TRPA1EGLN2AAK1AR | |
| SCHEMBL31030313 | 0.82 | TRPA1 (0.46) | TRPA1EGLN2GPR119AAK1CYP17A1 | |
| SCHEMBL6162554 | 0.80 | HTT (0.44) | TRPA1EGLN2GPR119AAK1CYP17A1 | |
| SCHEMBL29430885 | 0.80 | HTT (0.44) | TRPA1EGLN2GPR119AAK1CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11345672-B2 | Methods using HDAC11 inhibitors | VALO HEALTH, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-20190084946-A1 | METHODS USING HDAC11 INHIBITORS | Valo Health, LLC | 2019-03-21 | — | — | US | disclosed |
| US-20190084945-A1 | METHODS USING HDAC11 INHIBITORS | VALO HEALTH, INC. | 2019-03-21 | — | — | US | disclosed |
| US-20180127386-A1 | METHODS USING HDAC11 INHIBITORS | VALO EARLY DISCOVERY, INC. | 2018-05-10 | — | — | US | disclosed |
| WO-2018075959-A1 | METHODS USING HDAC11 INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2018-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11345672-B2 | Methods using HDAC11 inhibitors | HDAC11, HDAC1, HDAC10 | TRPA1 4882/4885EGLN2 834/4885GPR119 3622/4885 |
| US-20180127386-A1 | METHODS USING HDAC11 INHIBITORS | HDAC11, HDAC1, HDAC10 | TRPA1 4882/4885EGLN2 834/4885GPR119 3622/4885 |
| US-20190084945-A1 | METHODS USING HDAC11 INHIBITORS | HDAC11, HDAC1, HDAC10 | TRPA1 4882/4885EGLN2 834/4885GPR119 3622/4885 |
| US-20190084946-A1 | METHODS USING HDAC11 INHIBITORS | HDAC11, HDAC1, HDAC10 | TRPA1 4882/4885EGLN2 834/4885GPR119 3622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.